Permana Andhika Tomy, Bajamal Abdul Hafid, Parenrengi Muhammad Arifin, Suroto Nur Setiawan, Lestari Pudji, Fauzi Asra Al
Department of Neurosurgery Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia.
Department of Public Health, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia.
Surg Neurol Int. 2022 May 20;13:206. doi: 10.25259/SNI_1174_2021. eCollection 2022.
Several reports on stem cell administration have emerged proving it to be an ideal therapeutic approach for improving neurological functions in ischemic stroke patients. However, some studies also show disappointing results, with some reporting no statistically significant improvements among several different parameters. Several challenges also arise relating to safety and nonscientific aspects, such as ethics.
We performed a systematic review and meta-analysis to evaluate the effect of stem cell therapy on the clinical outcomes of ischemic stroke patients. A systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A thorough literature search was conducted on PubMed, Scopus, and Cochrane databases. Articles were selected systematically based on the PRISMA protocol and reviewed completely. A total of 19 publications pertaining to stem cell therapy on the ischemic route were included and reviewed. Efficacy outcomes were measured with the National Institutes of Health Stroke Scale, modified Rankin Scale, or Barthel Index.
The results of the meta-analysis indicate that the efficacy outcomes suggest favorable results after stem cell therapy, although not all study results are statistically significant. Stem cell therapy in stroke cases showed a better outcome than standard conservative therapy alone, although our analysis shows that many factors can influence this outcome, and significant effects can only be seen after several months.
The results of this study show promising and satisfying efficacy and a relatively low rate of serious adverse events.
已有多篇关于干细胞给药的报道,证明其是改善缺血性中风患者神经功能的理想治疗方法。然而,一些研究也显示出令人失望的结果,一些研究报告称在几个不同参数中没有统计学上的显著改善。还出现了一些与安全性和非科学方面(如伦理)相关的挑战。
我们进行了一项系统评价和荟萃分析,以评估干细胞治疗对缺血性中风患者临床结局的影响。根据系统评价和荟萃分析的首选报告项目(PRISMA)指南进行系统评价和荟萃分析。在PubMed、Scopus和Cochrane数据库上进行了全面的文献检索。根据PRISMA方案系统地选择文章并进行全面审查。总共纳入并审查了19篇关于缺血途径干细胞治疗的出版物。疗效结局采用美国国立卫生研究院卒中量表、改良Rankin量表或巴氏指数进行测量。
荟萃分析结果表明,尽管并非所有研究结果都具有统计学意义,但疗效结局表明干细胞治疗后有良好的结果。中风病例中的干细胞治疗显示出比单独的标准保守治疗更好的结局,尽管我们的分析表明许多因素会影响这一结局,且只有在几个月后才能看到显著效果。
本研究结果显示出有前景且令人满意的疗效,严重不良事件发生率相对较低。